Novo's Xultophy beats basal-bolus insulin at cutting hypoglycemia, spurring weight loss

11th June 2017 Uncategorised 0

Novo Nordisk is in a tough market race against Sanofi with combo product Xultophy, which hit the market after the French drugmaker’s Soliqua. New basal-bolus-topping data could give the med a leg up.

More: Novo's Xultophy beats basal-bolus insulin at cutting hypoglycemia, spurring weight loss
Source: fierce